<i>In vitro</i> evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy

Pei, Mengyue; Li, Huiyang; Zhu, Yingwei; Lü, Jian; Zhang, Chuangnian

doi:10.1039/d1bm02021h

Cited by 7 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neutrophils are frequently dominant and are linked to immunological escape from tumors ( 18 ). Consequently, these findings imply that FCN2 may suppress the HCC tumor immune response by favorably regulating neutrophils ( 19 , 20 ), eosinophils ( 21 ), NK cells ( 22 – 24 ), Tcm ( 25 ), and DCs ( 26 – 28 ) and negatively regulating Th2 ( 29 – 31 ) in tumors.…”

Section: Discussionmentioning

confidence: 93%

Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer

Wang

Zeng²,

Jiang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate the role of ficolin-2 (FCN2) in the development and course of hepatocellular carcinoma (HCC) and to contribute to the evolution of innovative HCC therapeutics.MethodsOncomine, GEPIA (Gene Expression Profiling Interactive Analysis), TISIDB (Tumor Immune System Interactions and Drug Bank database), UALCAN (University of Alabama at Birmingham Cancer data analysis portal), UCSC (University of California, Santa Cruz), R package, the Kaplan–Meier technique, Cox regression analysis, LinkedOmics, Pearson’s correlation, and a nomogram were used to investigate the prognostic value of FCN2 in HCC. Co-expressed genes were screened. A protein–protein interaction network was created using the STRING database. Finally, immunohistochemistry was performed to establish the expression of FCN2 in HCC tissues. A pan-cancer study centered on HCC-related molecular analysis was also conducted to look for a link between FCN2 and immune infiltration, immune modulators, and chemokine receptors.ResultsIn HCC tissues, the expression of FCN2 was observed to be lower than that in normal tissues. This was connected to the HCC marker alpha-fetoprotein, showing that FCN2 is involved in the development and progression of cancer. FCN2 may act through Staphylococcus aureus infection, lectins, and other pathways. Furthermore, at the immune level, the expression of FCN2 in HCC was associated with some immune cell infiltration, immunomodulators, and chemokine receptors.ConclusionFCN2 may be an immune checkpoint inhibitor for HCC, creating a breakthrough in the treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 93%

Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer

Wang

Zeng²,

Jiang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The enrichment analyses showed that the signature was associated with immune functions. Immunotherapy has currently been applied for the treatment of a variety of tumor types, including lung cancer 42 , melanoma 43 , cervical cancer 44 and liver cancer 45 . Immune checkpoints, for instance programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have the ability to encourage anticancer immune function 46 , 47 .…”

Section: Discussionmentioning

confidence: 99%

Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC

Wang

Xiao

2023

Sci Rep

View full text Add to dashboard Cite

Lung cancer is one of the most prevalent malignant tumors worldwide, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) accounting for the majority of cases. Cuproptosis, tumor immune microenvironment (TIME) and long non-coding RNA (lncRNA) have been demonstrated to be associated with tumorigenesis. The objective of the present study was to develop a novel cuproptosis-related lncRNA signature to assess the association between cuproptosis and TIME in patients with LUAD or LUSC and to predict prognosis. Based on the outputs of the least absolute shrinkage and selection operator regression model, a cuproptosis-related lncRNA signature was developed. Kaplan–Meier survival curves were generated to confirm the predictive ability of the signature. Univariate and multivariate analysis was also performed to determine the association between overall survival and this signature and other clinical characteristics, and a nomogram was created. Additionally, the relationship between the signature, TIME, tumor mutation burden and m6A methylation was established. The results of the present study revealed that 8 cuproptosis-related lncRNAs were associated with the prognosis of patients with LUAD and LUSC. This novel cuproptosis-related lncRNA signature is associated with TIME and m6A methylation in LUAD and LUSC and can predict prognosis with accuracy.

show abstract

“…Liver cancer immunotherapy has been the hotspot in liver cancer treatment. To induce anti-tumor immune responses, Pei et al ( Pei et al, 2022 ) designed nanovaccines consisting of polyanionic alginate (ALG) and polycationic polyethyleneimine (PEI) to co-deliver glypican-3 peptide antigens and unmethylated cytosine-phosphate-guanine adjuvants. The particle size of nanovaccines was 218 nm, and the zeta potential was 21 mV.…”

Section: Polymer-based Nanocarriers For Co-deliverymentioning

confidence: 99%

“…Researchers extracted the vesicles secreted by cancer cells to prepare drug delivery carriers, which effectively delivered drugs to cancer cells via direct fusion with cancer cells. Li et al (Li H. et al, 2022) used extracellular vesicles (EVs) as natural drug carriers to codeliver DOX and ronidamine (LND), a chemical sensitizer, for the treatment of lung cancer. They found that different centrifugal forces could affect the size of EVs, thus, affecting anti-cancer efficiency, and their results showed that smaller EVs had higher anti-cancer efficiency.…”

Section: Other Lipid-based Carriersmentioning

confidence: 99%

Nanoparticle drug delivery systems for synergistic delivery of tumor therapy

Chen

Liu²,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Nanoparticle drug delivery systems have proved anti-tumor effects; however, they are not widely used in tumor therapy due to insufficient ability to target specific sites, multidrug resistance to anti-tumor drugs, and the high toxicity of the drugs. With the development of RNAi technology, nucleic acids have been delivered to target sites to replace or correct defective genes or knock down specific genes. Also, synergistic therapeutic effects can be achieved for combined drug delivery, which is more effective for overcoming multidrug resistance of cancer cells. These combination therapies achieve better therapeutic effects than delivering nucleic acids or chemotherapeutic drugs alone, so the scope of combined drug delivery has also been expanded to three aspects: drug-drug, drug-gene, and gene-gene. This review summarizes the recent advances of nanocarriers to co-delivery agents, including i) the characterization and preparation of nanocarriers, such as lipid-based nanocarriers, polymer nanocarriers, and inorganic delivery carriers; ii) the advantages and disadvantages of synergistic delivery approaches; iii) the effectual delivery cases that are applied in the synergistic delivery systems; and iv) future perspectives in the design of nanoparticle drug delivery systems to co-deliver therapeutic agents.

show abstract

In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy

Abstract: Liver cancer is the most common malignant tumor and liver cancer immunotherapy has been one of the research hotspots. To induce antigen-specific antitumor immune responses against liver cancer, we developed...

Cited by 7 publications

References 43 publications

Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer

Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer

Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC

Nanoparticle drug delivery systems for synergistic delivery of tumor therapy

Contact Info

Product

Resources

About